Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis
- 12 January 2015
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 21 (12), 1521-1532
- https://doi.org/10.1177/1352458514564589
Abstract
In multiple sclerosis (MS), disturbed T-cell homeostasis affects both conventional CD4+ T cells (Tcon) and regulatory T cells (Treg). Functionally, this is linked to a loss of Treg-suppressive properties. Concerns exist as to whether fingolimod might further aggravate Treg dysfunction by inhibiting thymic egress and, thus, promoting premature immunosenescence. The objective of this paper is to investigate whether fingolimod, by sequestration of developing cells in the thymus, might deteriorate numeric and/or functional disequilibrium of T-cell subtypes. We assessed numbers and phenotypes of blood Tcon and Treg in 74 MS patients treated with fingolimod and in 37 healthy donors. Treg and Tcon were also analyzed for immunoreactivity, suppressive function, sphingosine-1-phosphate-triggered (S1P) trafficking, and S1P-receptor expression. This was complemented by assessing surrogate markers of thymic T-cell development, including frequencies of cells expressing T-cell receptors (TCR) of dual specificity, and TCR diversity in Treg. Fingolimod did not negatively affect naive T-cell phenotypes or markers of thymic T-cell development. By reducing CCR7-expressing Tcon, fingolimod increased relative proportions of Treg. As a result of this shift, fewer proliferative CCR7− Tcon became enriched and Treg-dysfunction was indirectly reversed. These observations argue against harmful interference of fingolimod with thymic T-cell output that, particularly in pediatric MS, might possibly counteract its beneficial effects.Keywords
This publication has 38 references indexed in Scilit:
- T-cell homeostasis in pediatric multiple sclerosisNeurology, 2013
- Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MSNeurology, 2011
- Differential responses of human microglia and blood-derived myeloid cells to FTY720Journal of Neuroimmunology, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- The receptor S1P1 overrides regulatory T cell–mediated immune suppression through Akt-mTORNature Immunology, 2009
- Immunomodulatory drug FTY720 induces regulatory CD4+CD25+ T cells in vitroClinical and Experimental Immunology, 2009
- Development of regulatory T cells requires IL-7Rα stimulation by IL-7 or TSLPBlood, 2008
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999